Company Revenue Reports

Company orthopedic sales declined -3.7% in 4Q due to the surging pandemic, dropping full-year 2020 sales to -12.2% vs. the prior year.

With its renewed focus on winning market share, Medtronic estimates Mazor X placements outpaced Globus Medical's ExcelsiusGPS by a factor of 1.5 in 3Q20.

The company grew +3.6% for their fiscal 1Q21, however the second wave of rapid COVID spread has significantly reduced case volumes through November.

The company rebounded sequentially in 3Q20 while sharpening its focus on digital surgery as a strategic initiative with the acquisition of Holo Surgical.

The company's MACI revenue grew +18.2% in 3Q20 while record numbers of new biopsies point toward a sequential step up in fourth quarter revenue.

The company grew 7% in 3Q20 as growth in U.S. trauma sales more than offset continuing COVID-related challenges in international markets.

The company's joint replacement business grew over 9% in 3Q20 as it prepares to enter the high-growth foot and ankle joint replacement market.

Despite gaining market share in Japan, the company's sales dropped by double-digits for the third consecutive quarter due to COVID and price reductions.

The company grew +8.3% in 3Q20 due to its new product cadence, contracting wins in large health systems and geographic expansion of its revenue footprint.

U.S. spinal sales drove Orthofix's sequential improvement in 3Q20 but were not enough to overcome lingering procedure volume declines due to COVID.